Bioprojet Pharma — Sponsor Intelligence | 17 EU Trials

Filter these 17 trials by condition, phase, country and more.

Open in Search →

17 Registered trials

6 Recruiting

12 Completed trials

7 Countries active

3 Unique IMPs

100% Results reported

Phase II

Phase I (Other)

Phase III: 1 Phase II: 7 Phase I: 1 Phase I (Other): 8

100%

12 of 12 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Narcolepsy 5 Eosinophilic oesophagitis 2 Binge eating 2 Autism spectrum disorder 1 Essential tremor 1 Premature ejaculation 1 Dermatitis atopic 1 Obsessive-compulsive disorder 1

Top IMPs

N-[4-[2-[4-(3-CYANOPHENYL)PIPERAZIN-1-YL]ETHYL]CYCLOHEXYL]-3-METHOXYPROPANAMIDE 4 BP1.7881A 2 PITOLISANT 2

All trials

17 total

A medical study testing the safety and effectiveness of BP1.4979, a new drug for adults with obsessive-compulsive disorder. Recruiting

2025-522026-13-00 Phase II 4 countries N-[4-[2-[4-(3-CYANOPHENYL)PIPERAZIN-1-YL]ETHYL]CYCLOHEXYL]-3-METHOXYPROPANAMIDE
A first-in-human, randomized, double-blind, placebo-controlled, three-part study assessing the safety, tolerability, pharmacokinetics and ph… Recruiting

2025-521556-35-00 Phase I 1 country
A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of BP1.4979 in adult p… Recruiting

2024-517987-46-00 Phase II 1 country N-[4-[2-[4-(3-CYANOPHENYL)PIPERAZIN-1-YL]ETHYL]CYCLOHEXYL]-3-METHOXYPROPANAMIDE
A multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of BP1.4979 in adult p… Recruiting

2024-517996-19-00 Phase II 1 country N-[4-[2-[4-(3-CYANOPHENYL)PIPERAZIN-1-YL]ETHYL]CYCLOHEXYL]-3-METHOXYPROPANAMIDE
Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administere… Recruiting

2024-512722-28-00 Phase I (Other) 1 country
A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2 trial to evaluate the efficacy and safety of BP1.7881 in… Recruiting

2023-508949-40-00 Phase II 2 countries BP1.7881A
Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulatio… Ended

2025-520980-41-00 Phase I (Other) 1 country
Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation… Ended

2024-513383-26-00 Phase I (Other) 1 country
Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.497… Ended

2024-512355-20-00 Phase I (Other) 1 country
Exploratory study to assess the pharmacokinetic interaction of doxepin with adrenaline after a concomitant co-administration using the Anape… Ended

2023-508117-16-00 Phase I (Other) 1 country
Open label, single-center, four-part registration pharmacokinetic study: Part I: Pilot 2-way cross-over randomized, comparative pharmacokine… Ended

2023-507316-12-00 Phase I (Other) 1 country
An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children a… Ended

2023-503678-18-00 Phase II 4 countries PITOLISANT
Open label, single-center, cross-over randomized, relative bioavailability study comparing 4 new BF2.649 (pitolisant) tablet formulations ve… Ended

2023-505769-98-00 Phase I (Other) 1 country
A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.78… Ended

2022-502045-10-00 Phase II 3 countries BP1.7881A
Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant a… Ended

2023-503945-78-00 Phase I (Other) 1 country
A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder. Ended

2023-506511-17-00 Phase II 2 countries N-[4-[2-[4-(3-CYANOPHENYL)PIPERAZIN-1-YL]ETHYL]CYCLOHEXYL]-3-METHOXYPROPANAMIDE
Double blind, multicentre, randomized, placebo-controlled trial to evaluate safety and efficacy of pitolisant in children from 6 to less tha… Ended

2024-515568-30-00 Phase III 2 countries PITOLISANT

Showing 1–17 of 17 trials

← All sponsors A–Z